Main Article Content


There has been a tremendous increase in interest for transdermal drug delivery system for sustain release dosage form in disease conditions like hypertension, muscle relaxation, diabetes, etc to reduce the frequency of dosing and to improve patient compliance. Matrix diffusion controlled release system patches of Tizanidine hydrochloride were formulated to achieve sustain release pattern within the therapeutic range. HPMC K15, Ethyl cellulose, Sodium alginate were used as matrix forming polymers and propylene glycol, oleic acid were used as plasticizer and permeation enhancer respectively. Methanol and water were used as solvents. Patches were prepared by solvent casting method. Prepared patches were evaluated for physicochemical parameters like weight variation, thickness, folding endurance, drug content, moisture uptake, moisture loss. Patches prepared, from each batch, gave release profile for over 24hrs. Cumulative amount drug releases in 24hrs for all prepared formulations were found to be in the following order: F1>F2>F9>F7>F8>F5>F6>F3>F4. Among all the formulations, the F1 shows the maximum drug release from system i.e. 88.37% at the end of 24hrs. The other formulation F4 shows the minimum drug release from system i.e. 69.9%. Based on the formulations physicochemical parameters evaluation and in-vitro drug release studies, formulation F1 selected for further studies. Skin irritation test was performed on Albino rabbits for F1. There were no signs of redness or erythema. Hence, it can be reasonably concluded that Tizanidine Hydrochloride can be formulated into the Transdermal matrix type patches to sustain its release characteristics


Sustain release patches, Tizanidine hydrochloride, diffusion studies

Article Details

How to Cite
Shruthi.Y, Dr.Annabalaji. FORMULATION AND EVALUATION OF TIZANIDINE HYDROCHLORIDE TRANSDERMAL PATCH. Int. j. innov. pharm. sci. res. [Internet]. 2013Apr.24 [cited 2023Jun.1];1(4):484-98. Available from: